Bolsas y Mercados Españoles
Company
search
LABORATORIOS FARMACEUTICOS ROVI, S.A.
AddressCL JULIAN CAMARILLO 35, 28037 MADRID 
Listed Capital3,364,137.90 Euros

 


LABORATORIOS ROVI
ISINES0157261019 TickerROVI Nominal0.06 MarketContinuous Market Admitted Capital3,364,137.90 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
03/07/2020Close26.200025.20003.9726.200026.200025.200025.788023,579608,056.40
X
03/07/2020 17:37:08
BidAsk
OrdersVolumePricePriceVolumeOrders
16625.900026.20001973
110525.800026.30001,0186
110525.700026.40001411
11725.000026.50003512
15024.800026.60004863

Last pay
TypeEx-datePayment DateConcept
Dividend02/07/201904/07/2019Annual 2018

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
01/11/201899 x 10,000Premium


 2020
until 3/07
2019201820172016
Capitalisation *
(thousands of euros)
1,469,0071,368,083978,403782,500616,500
Shares
(x 1,000)
56,06956,06956,06950,00050,000
Period Close Price
(euros)
26.200024.400017.450015.650012.3300
Period Last Price
(euros)
26.200024.400017.450015.650012.2400
Period High Price
(euros)
27.100025.500018.150018.750015.3800
Period Low Price
(euros)
20.000016.900014.800012.150010.8000
Volume
(thousands of shares)
4,7685,4009,9712,0385,616
Turnover
(thousands of euros)
114,421109,782153,17931,12078,378

Profile

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs.

The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin.

ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISMTM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments.

ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction.

Source: Issuing company.
04/07/2020 00:56:32

Video Gallery

Research

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2020